Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Nabriva Therapeutics announced earnings per share of $-0.09 on revenue of $1.29M. Analysts polled by Investing.com anticipated EPS of $-0.1 on revenue of $1.12M.
Nabriva Therapeutics shares are down 63.03% from the beginning of the year, still down 78.12% from its 52 week high of $2.23 set on November 13, 2019. They are under-performing the Nasdaq which is up 32.52% from the start of the year.
Nabriva Therapeutics follows other major Healthcare sector earnings this month
Nabriva Therapeutics's report follows an earnings beat by J&J on October 13, who reported EPS of $2.2 on revenue of $21.08B, compared to forecasts EPS of $1.98 on revenue of $20.2B.
Thermo Fisher Scientific had beat expectations on October 21 with third quarter EPS of $5.63 on revenue of $8.52B, compared to forecast for EPS of $4.33 on revenue of $7.65B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar